Indication hub
Hypertension clinical trials — Miami
Amavita Research is the GCSA-certified Miami cardiovascular trial site: senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background, an in-house South Florida heart practice, and a dedicated cardiovascular ASC.
Hypertension protocols at Amavita Research are conducted from the North Miami Beach research suite. The public homepage study in this indication is ZENITH. Dr. Pedro Martinez-Clark is a principal investigator. Dr. William W. O'Neill is the senior PI.
Public studies
- Phase 3EnrollingZENITH — Zilebesiran in Uncontrolled Hypertension
Sponsor: Alnylam Pharmaceuticals
Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.
Investigators
Why Amavita Research for hypertension
- In-house South Florida heart practice for hypertensive patient identification.
- Operating legal address, clinical trial site and heart practice at 100 NW 170 St, Suite 305, North Miami Beach, FL 33169.
- Operating cardiovascular ASC at 9408 SW 87th Ave, Suite 303, Miami, FL 33176.
- IAOCR GCSA-certified (Feb 2025). ICH-GCP E6(R3).
New-sponsor first-touch
Julio G. Martinez-Clark
CEO, Amavita Research Services, LLC
New-sponsor first-touch, CDA, and NDA. Julio signs CDAs. Dr. Pedro Martinez-Clark is a principal investigator only. After a study is awarded, Nereisy Alonso, Sr CRC, COO owns study operations: monitors and start-up logistics.
Contact Julio about a protocolLocations
Where this work happens
- Operating North Miami Beach location at 100 NW 170 St, Suite 305. This is the legal address, clinical trial site and heart practice.
- Operating Kendall cardiovascular surgery center at 9408 SW 87th Ave, Suite 303, Miami, FL 33176.